At iHealth Pharma Limited, we deploy strategic capital into pioneering healthcare ventures, driving breakthrough biotechnologies and building sustainable long-term global health solutions.
Explore Our 2027 Strategy →A UK-registered investment platform with a clear healthcare focus.
Expanding our venture portfolio across early to mid-stage pharmaceutical, medical technology, and digital health initiatives worldwide.
Transitioning R&D insights into market-ready proprietary medical devices and branded pharmaceutical formulations.
Establishing robust international supply chains and commercial networks worldwide.
Spun out from the University of Oxford, Oxford Brain Diagnostics (OBD) is pioneering early detection of neurodegenerative conditions using their breakthrough Cortical Disarray Measurement (CDM®) technology.
CDM® analyses microscopic brain cellular structures directly from standard MRI scans, enabling clinicians and biopharmaceutical partners to predict, detect, track, and monitor Alzheimer's disease and Parkinson's disease years before macrostructural damage appears.
Visit Corporate Website ↗
CDM Insights™
Quantifies changes in grey matter microstructural integrity at cellular resolution directly from standard MRI scans.
Partnered with global pharma leaders including AbbVie & NeuroTherapia for targeted, efficient clinical trial endpoints.
Seamlessly integrates with hospital PACS networks to return automated diagnostic reports within 12 hours.
Further announcements regarding expanding investments in biotechnology, medical devices, and healthtech will follow.